Managing Toxicities of HER2+ Therapies in Upper GI Cancer - Trastuzumab, T-DXd, Zanidatamab

Welcome to the Oncology Brothers podcast! In this episode, we dived into the latest advancements in HER2-targeted therapies for upper gastrointestinal malignancies, with Drs. Shruti Patel and Samuel Cytryn.

Join us as we discussed:

The recent approval of zanidatamab and its implications for HER2-positive esophageal and gastric adenocarcinoma

The role of trastuzumab in treatment and its associated side effects, including cardiotoxicity and infusion reactions

Addressing different dose used for trastuzumab deruxtecan (T-DXd) in upper GI space, along with important side effect profile to keep in mind

The importance of shared decision-making in treatment options and the impact of dosing strategies on patient outcomes

We also covered the critical need for biomarker-driven treatment approaches, including HER2 status and PD-L1 scores, and how these factors influence therapy choices.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

⁠X/Twitter: https://x.com/oncbrothers

⁠Instagram: https://www.instagram.com/oncbrothers